PHASE II CLINICAL TRIALS OF NEW CHEMOPREVENTIVE AGENTS
NIH GUIDE, Volume 23, Number 7, February 18, 1994
RFP AVAILABLE: NCI-CN-45593-32
P.T.
Keywords:
National Cancer Institute
The National Cancer Institute (NCI) is seeking contractors qualified
to perform Phase II Clinical Trials that are small short-term,
efficient studies of potential chemopreventive agents. This work
includes small, short-term, efficient studies to determine the dose
of a given chemopreventive agent that exhibits a pharmacodynamic
effect on an intermediate endpoint. These studies will also require
dose response studies to determine the minimum dose at which a
biological effect is observed and confirmation of the maximum safe
dose, and the performance of randomized blinded trials in small
groups of subjects whose endpoints will be the measurable biological
effect of the agent versus a placebo. This solicitation is an annual
announcement to expand a current pool of Master Agreement (MA)
Holders qualified to perform this type of work. Individual work
requirements will be defined, as the need arises, by Master Agreement
Orders issued during the period of performance, and Master Agreement
Orders will be awarded based on competition between members of the MA
pool. The solicitation will be released on or about February 22,
1994, with proposals due April 22, 1994.
INQUIRIES
The Contracting Officer for this solicitation is Richard L. Hartmann
on telephone (301) 496-8603. Copies of the RFP may be obtained by
sending a written request to:
Ms. Desiree Sylver-Foust
Research Contracts Branch
National Cancer Institute
Executive Plaza South, Room 635
Bethesda, MD 20892
Telephone: (301) 496-8603
.